



Nevada PEBP

Q1 FY2024

Prepared by Client Analytics

Cynthia Eaton (cynthia.eaton@express-scripts.com)

12.15.23

**The data contained herein is pulled from a specific point-in-time and is subject to change at any time without notice due to a variety of factors, including but not limited to changes related to Member behavior, population demographics, system updates, and product availability. The data does not represent a guarantee and should not be used for audit purposes.*

Hello PEBP Team,

This is the Q1 FY24 Summary File for the three State of Nevada PEBP plans (CDHP, EPO, and PPO). The summary contains Trend breakouts for each plan (Utilization, Unit Cost, and Cost Share). Along with the most notable changes of drugs within the top moving indications. Each plan breakout has a peer comparison of Trend. The file concludes with several Key Statistics of the three plans in aggregate.

CDHP Overall Trend Summaries:

CDHP Overall Trend		% Change
Current Period - Plan Cost Net PMPM	\$62.41	
Utilization	\$2.72	4.4%
Unit Cost	(\$1.53)	(2.5%)
Member Share	(\$0.01)	(0.0%)
Total Change in Plan Cost Net PMPM	\$1.17	1.9%
Previous Period - Plan Cost Net PMPM	\$61.24	

Top moving indications and most notable drug changes within the indications are as follows:

- **Cancer:** Previous ranked 2nd, currently ranked 7th by Plan Cost Net.
 - Plan Cost Net ↓ \$239k (-22.5%) to current \$822k.
 - Plan Cost Net PMPM ↓ \$1.25 (-10.0%) to current \$11.24.
 - Patient Count ↑ 3 to current count of 165.
 - Adjusted Rx's ↓ 2 to current count of 461.
- **Notable Drug Changes within Indication:**
 - **Lenalidomide (Generic for Revlimid)**
 - Top ranking drug for cancer indication by Plan Cost Net.
 - Plan Cost Net: New, current \$113k.
 - Plan Cost Net PMPM: New, current \$1.54.
 - Patient Count: New, current count of 3.
 - Adjusted Rx's: New, current count of 9.
 - **Onureg**
 - Currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net: New, current \$95k.
 - Plan Cost Net PMPM: New, current \$1.30.
 - Patient Count: New, current count of 1.
 - Adjusted Rx's: New, current count of 4.
 - **Revlimid**
 - Previous ranked 1st, currently ranked 9th by Plan Cost Net.

- Plan Cost Net ↓ \$167k (-82.8%) to current \$35k.
 - Plan Cost Net PMPM ↓ \$1.90 (-80.0%) to current \$.47.
 - Patient Count ↓ 2 to current count of 2.
 - Adjusted Rxs ↓ 10 to current count of 3.
- **Ophthalmic Conditions:** Previous ranked 13th, currently ranked 7th.
 - Plan Cost Net ↑ \$113k (115.3%) to current \$210k.
 - Plan Cost Net PMPM ↑ \$1.73 (115.3%) to current \$2.88.
 - Patient Count ↓ 8 to current count of 145.
 - Adjusted Rxs ↑ 26 to current count of 246.
- **Notable Drug Changes within Indication:**
 - **Tepezza**
 - Previous ranked 1st, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$96k (165.8%) to current \$153k.
 - Plan Cost Net PMPM ↑ \$1.42 (209%) to current \$2.10.
 - Patient Count remains at 1.
 - Adjusted Rxs ↑ 2 to current count of 3.
 - **Eylea**
 - Previous ranked 2nd, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net ↑ \$27k (98.8%) to current \$55k.
 - Plan Cost Net PMPM ↑ \$.43 (131.1%) to current \$.75.
 - Patient Count ↑ 4 to current 12.
 - Adjusted Rxs ↑ 15 to current count of 30.
 - **Other drug changes in this indication were not notable.**
- **Neuromyelitis Optica Spectrum Disorder:** New, currently ranked 10th
 - Plan Cost Net: New, current \$130k.
 - Plan Cost Net PMPM: New, current \$1.77.
 - Patient Count: New, current count of 1.
 - Adjusted Rxs: New, current count of 6.
- **Notable Drug Changes within Indication:**
 - **Uplizna**
 - New, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net: New, current \$130k.
 - Plan Cost Net PMPM: New, current \$1.77.
 - Patient Count: New, current count of 1.
 - Adjusted Rxs: New, current count of 6.
 - **No other drugs utilized within this indication.**

Peer Comparison:

- Peer: ESI CDH Program
- PEBP CDHP is outperforming the peer.
- Peer experienced Plan Cost Net PMPM of \$83.14 compared to CDHP PEBP of \$62.41.
- Peer experienced Trend of 9.9%, compared to CDHP PEBP Trend of 1.9%

EPO Overall Trend Summaries:

EPO Overall Trend		% Change
Current Period - Plan Cost Net PMPM	\$160.53	
Utilization	\$5.10	3.5%
Unit Cost	\$3.05	2.1%
Member Share	\$4.87	3.3%
Total Change in Plan Cost Net PMPM	\$13.02	8.8%
Previous Period - Plan Cost Net PMPM	\$147.51	

Top moving indications and most notable drug changes within the indications are as follows:

- **Endocrine Disorders:** Previous ranked 3rd, currently ranked 2nd.
 - Plan Cost Net ↑ \$82k (25.6%) to current \$402k.
 - Plan Cost Net PMPM ↑ \$6.94 (43.2%) to current \$22.98.
 - Patient Count ↓ 5 to current count of 20.
 - Adjusted Rxs ↓ 13 to current count of 53.
- **Notable Drug Changes within Indication:**
 - **Korlym**
 - Previous ranked 1st, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$102k (35.8%) to current \$386k.
 - Plan Cost Net PMPM ↑ \$7.82 (54.9%) to current \$22.08.
 - Patient Count ↑ 1 to current count of 2.
 - Adjusted Rxs ↑ 3 to current count of 7.
 - **Somatuline Depot**
 - Previous ranked 2nd, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net ↓ \$13k (-49.5%) to current \$13k.
 - Plan Cost Net PMPM ↓ \$.56 (-42.4%) to current \$.76.
 - Patient Count ↑ 1 to current count of 2.
 - Adjusted Rxs ↓ 12 to current count of 2.
 - **Other drug changes in this indication were not notable.**

- **Narcolepsy:** Previous ranked 21st, currently ranked 7th.
 - Plan Cost Net ↑ \$45k (125.4%) to current \$81k.
 - Plan Cost Net PMPM ↑ \$2.82 (157%) to current \$4.62.
 - Patient Count ↑ 1 to current count of 2.
 - Adjusted Rxs ↑ 4 to current count of 7.

- **Notable Drug Changes within Indication:**
 - **Sodium Oxybate**
 - New, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net: New, current \$11k.
 - Plan Cost Net PMPM: New, current \$2.62.
 - Patient Count: New, current count of 1
 - Adjusted Rxs: New, current count of 4
 - **Wakix**
 - New, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net: New, current \$12k.
 - Plan Cost Net PMPM: New, current \$2.01.
 - Patient Count: New, current 1.
 - Adjusted Rxs: New, current count of 3.
 - **No other drugs utilized within this indication.**

- **Ophthalmic Conditions:** Previous ranked 10th, currently ranked 20th.
 - Plan Cost Net ↓ \$50k (-66.8%) to current \$25k.
 - Plan Cost Net PMPM ↓ \$2.32 (-62.2%) to current \$1.41.
 - Patient Count ↓ 11 to current count of 41.
 - Adjusted Rxs ↑ 26 to current count of 246.

- **Notable Drug Changes within Indication:**
 - **Oxervate**
 - Previous ranked 1st, currently no utilization.
 - Plan Cost Net ↓ \$53k (-100%) to current \$0.
 - Plan Cost Net PMPM ↓ \$2.64 (-100%) to current \$0.
 - Patient Count ↓ 1 to current count of 0.
 - Adjusted Rxs ↑ 15 to current count of 30.
 - **Other drug changes in this indication were not notable.**

Peer Comparison:

- Government – West Region/SaveOn (custom peer created for PEBP EPO plan)
- The peer is outperforming PEBP EPO.
- Peer experienced Plan Cost Net PMPM of \$99.80 compared to PEBP EPO of \$147.51
- Peer experienced Trend of 6.2%, compared to PEBP EPO of 8.8%

PPO Overall Trend Summaries:

PPO Overall Trend		% Change
Current Period - Plan Cost Net PMPM	\$91.51	
Utilization	\$2.20	2.7%
Unit Cost	\$6.41	7.9%
Member Share	\$1.85	2.3%
Total Change in Plan Cost Net PMPM	\$10.47	12.9%
Previous Period - Plan Cost Net PMPM	\$81.04	

Top moving indications and most notable drug changes within the indications are as follows:

- **Inflammatory Conditions:** Previous ranked 1st, currently ranked 1st.
 - Plan Cost Net ↑ \$405k (58.6%) to current \$1.1m.
 - Plan Cost Net PMPM ↑ \$3.09 (18.3%) to current \$20.03.
 - Patient Count ↑ 62 to current count of 189.
 - Adjusted Rxs ↑ 205 to current count of 616.
- **Notable Drug Changes within Indication:**
 - **Humira (CF) Pen**
 - Previous ranked 1st, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$75k (32.4%) to current \$307k.
 - Plan Cost Net PMPM ↓ \$.07 (-1.2%) to current \$5.61.
 - Patient Count ↑ 7 to current count of 27.
 - Adjusted Rxs ↑ 19 to current count of 73.
 - **Stelara**
 - Previous ranked 4th, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net ↑ \$102k (224.7%) to current \$147k.
 - Plan Cost Net PMPM ↑ \$1.58 (142.2%) to current \$2.68.
 - Patient Count ↑ 5 to current count of 10.
 - Adjusted Rxs ↑ 14 to current count of 30.
 - **Rinvoq**
 - Previous ranked 11th, currently ranked 4th by Plan Cost Net.
 - Plan Cost Net ↑ \$71k (587.2%) to current \$83k.
 - Plan Cost Net PMPM ↑ \$1.22 (412.6%) to current \$1.51.
 - Patient Count ↑ 6 to current count of 8.
 - Adjusted Rxs ↑ 20 to current count of 24.
- **Diabetes:** Previous ranked 2nd, currently ranked 2nd.
 - Plan Cost Net ↑ \$329k (80.7%) to current \$737k.
 - Plan Cost Net PMPM ↑ \$3.47 (34.8%) to current \$13.45.
 - Patient Count ↑ 365 to current count of 1,009.

- Adjusted Rxs ↑ 2,018 to current count of 5,454.
- **Notable Drug Changes within Indication:**
 - **Ozempic**
 - Previous ranked 1st, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net ↑ \$120k (112%) to current \$227k.
 - Plan Cost Net PMPM ↑ \$1.52 (58.1%) to current \$4.14.
 - Patient Count ↑ 98 to current count of 193.
 - Adjusted Rxs ↑ 318 to current count of 577.
 - **Mounjaro**
 - Previous ranked 11th, currently ranked 2nd by Plan Cost Net.
 - Plan Cost Net ↑ \$126k (1,940.6%%) to current \$133k.
 - Plan Cost Net PMPM ↑ \$2.26 (1,422%) to current \$2.42.
 - Patient Count ↑ 96 to current count of 103.
 - Adjusted Rxs ↑ 301 to current count of 314.
 - **Rybelsus**
 - Previous ranked 6th, currently ranked 5th by Plan Cost Net.
 - Plan Cost Net ↓ \$21k (160.2%) to current \$33k.
 - Plan Cost Net PMPM ↑ \$.29 (94.1%) to current \$.61.
 - Patient Count ↑ 16 to current count of 26.
 - Adjusted Rxs ↑ 52 to current count of 85.
- **Ophthalmic Conditions:** Previous ranked 22nd, currently ranked 6th.
 - Plan Cost Net ↑ \$265k (716.5%) to current \$302k.
 - Plan Cost Net PMPM ↑ \$4.61 (509.0%) to current \$5.52.
 - Patient Count ↑ 39 to current count of 110.
 - Adjusted Rxs ↑ 97 to current count of 232.
- **Notable Drug Changes within Indication:**
 - **Tepezza**
 - New, currently ranked 1st by Plan Cost Net.
 - Plan Cost Net: New, current \$247k.
 - Plan Cost Net PMPM: New, current \$4.51.
 - Patient Count: New, current count of 1.
 - Adjusted Rxs: New, current count of 4.
 - **Other drug changes in this indication were not notable.**

Peer Comparison:

- Government – West Region/SaveOn (custom peer created for PEBP PPO plan)
- PEBP PPO is outperforming the peer in Plan Cost Net, however PEBP PPO experienced a higher Trend.
- PEBP PPO experienced Plan Cost Net PMPM of \$91.51 compared to peer of \$99.80.
- Peer experienced Trend of 6.2%, compared to PEBP PPO of 12.9%.

Total Overall Trend		% Change
Current Period - Plan Cost Net PMPM	\$85.14	
Utilization	\$2.30	2.9%
Unit Cost	\$1.73	2.2%
Member Share	\$2.52	3.2%
Total Change in Plan Cost Net PMPM	\$6.55	8.3%

Previous Period - Plan Cost Net PMPM **\$78.59**

Summary of Total – Overall the main driver of Trend was Specialty Utilization driven by an increase of 14.4% in Specialty patients. This resulted in an 18.8% increase in Specialty Days of Therapy.

Trend was mitigated by increased rebates of 40.6%. This produced a negative Unit Cost Trend of (-13.3%) on Specialty drugs and reduced NonSpecialty Unit Cost Trend to 1.5%, combined is 2.2%.

Member Cost contributed to Trend on both Specialty and NonSpecialty drugs. This is due to increased Utilization on Specialty drugs and Drug Mix on NonSpecialty drugs. Primary driven by utilization of more expensive brand drugs.

Key Statistics:

Description	Nevada PEBP Total		
	Q1 FY23	Q1 FY24	Change
Average Members per Month	48,446	48,586	-0.3%
Number of Unique patients	24,546	25,166	-2.5%
Members Utilizing the Benefit	50.7%	51.8%	-1.1
Gross Cost/Adjusted Rx	\$136.86	\$122.29	11.9%
Plan Spend	\$19,816,299	\$21,395,922	18.3%
Rebates (estimated)	\$7,442,446	\$5,292,515	40.6%
Plan Cost Net	\$12,373,853	\$11,454,879	8.0%
Plan Cost Net PMPM	\$85.14	\$78.59	8.3%
Non-Specialty Plan Cost Net PMPM	\$36.49	\$33.88	7.7%
Specialty Plan Cost Net PMPM	\$48.65	\$44.71	8.8%
Generic Fill Rate	86.5%	85.7%	0.8
90 Day Utilization	61.4%	61.8%	-0.4
Retail - Maintenance 90 Utilization	28.4%	30.6%	-2.1
Home Delivery Utilization	32.9%	31.2%	1.7
Member Cost Net %	26.7%	28.9%	-2.2

END OF REPORT